Compare INVE & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INVE | IMA |
|---|---|---|
| Founded | 1990 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.1M | 66.3M |
| IPO Year | 1997 | 2021 |
| Metric | INVE | IMA |
|---|---|---|
| Price | $2.61 | $5.05 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | $5.50 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 159.3K | 11.1K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $60,219,000.00 | $800,000.00 |
| Revenue This Year | $22.10 | N/A |
| Revenue Next Year | $20.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.21 | N/A |
| 52 Week Low | $2.42 | $3.94 |
| 52 Week High | $5.30 | $9.10 |
| Indicator | INVE | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 37.90 | 36.03 |
| Support Level | $2.46 | $4.73 |
| Resistance Level | $2.79 | $6.13 |
| Average True Range (ATR) | 0.10 | 0.29 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 10.59 | 20.45 |
Identiv Inc develops specialty radio-frequency identification (RFID) and Internet of Things It (IoT) solutions that address customers' challenges and create new opportunities for them through the digitization and enhanced connectivity to the IoT. It designs, produces, and sells RFID and Bluetooth Low Energy (BLE) enabled devices, RFID inlays, tags, and labels that can be applied or incorporated into physical objects, providing them with a digital identity and the ability for customers to track, monitor, authenticate, and engage with consumers. Its IoT Business segment develops, manufactures, and supplies specialty IoT solutions tailored for the healthcare, logistics, smart packaging industries and other high-value end markets.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.